US 11,744,822 B2
Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
Israel Charo, Mountain View, CA (US); Heiyoun Jung, Menlo Park, CA (US); Thomas J. Schall, Menlo Park, CA (US); and Penglie Zhang, Foster City, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., Mountain View, CA (US)
Filed on Jan. 14, 2020, as Appl. No. 16/742,139.
Application 16/742,139 is a division of application No. 15/480,992, filed on Apr. 6, 2017, granted, now 10,568,870.
Claims priority of provisional application 62/319,689, filed on Apr. 7, 2016.
Prior Publication US 2020/0289472 A1, Sep. 17, 2020
Int. Cl. A61K 39/00 (2006.01); A61K 31/4192 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/496 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01)
CPC A61K 31/4192 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4178 (2013.01); A61K 31/496 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/3015 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/76 (2013.01)] 10 Claims
 
1. A method for treating a subject having a solid tumor expressing PD-1, said method comprising administering to the subject in need thereof a therapeutically effective amount of a CCR1 chemokine receptor antagonist, and a therapeutically effective amount of a PD-1 inhibitor,
wherein the CCR1 chemokine receptor antagonist has the formula (IIIb1a):

OG Complex Work Unit Chemistry
wherein each A is N or CH and at least one A is N; R1 is halogen; R3 is selected from the group consisting of C1-8 alkyl, C3-8 cycloalkyl and C2-8 alkenyl; and R8 is C1-8 alkyl; or a pharmaceutically acceptable salt thereof, and
wherein the solid tumor is triple negative breast cancer.